February 16th 2024
The FDA has granted an orphan drug designation to tigilanol tiglate for the treatment of soft tissue sarcoma.
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
T-Cell Therapy Granted FDA Breakthrough Designation in Sarcoma
February 11th 2016The FDA has granted an affinity enhanced T-cell therapy breakthrough therapy designation for patients with inoperable or metastatic pretreated synovial sarcoma who harbor HLA-A*201, HLA-A*205, or HLA-A*206 alleles and whose tumors express the NY-ESO-1 tumor antigen
Read More
Eribulin Approved by FDA for Treatment of Advanced Liposarcoma
January 29th 2016The FDA has approved eribulin mesylate (Halaven) as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy, based on an improvement in overall survival (OS) in a phase III study.
Read More
MAESTRO Trial Shows Evofosfamide Provides Little Benefit in STS
January 28th 2016The results from MAESTRO, a phase III trial examining evofosfamide in advanced pancreas cancer patients, show the treatment offers little-to-no advantage to both patients with pancreatic cancer and soft tissue sarcoma (STS) were presented at an oral session at the ASCO Gastrointestinal Cancers Symposium.
Read More
Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue Sarcoma
December 4th 2015Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma.
Watch
Addition of Olaratumab to Doxorubicin Extends Survival by Nearly One Year in Soft Tissue Sarcoma
November 7th 2015The addition of olaratumab to doxorubicin improved overall survival (OS) by nearly 1 year in patients with advanced soft tissue sarcoma, according to final results of a phase Ib/II study.
Read More